Frank Stokes
Known title: Chief Financial OfficerCIK: 0001782815
Associated companies
Transaction History
| CSTL | ▼ Sell | Open Market | 24,908 | $742K | 8/14/2026 | View on chart |
| CSTL | ▼ Sell | Open Market | 6,001 | $168K | 3/5/2026 | View on chart |
| CSTL | ▲ Buy | Option Exercise | 24,146 | — | 3/4/2026 | View on chart |
| CSTL | ▼ Sell | Tax Withholding | 10,732 | $302K | 3/4/2026 | View on chart |
| CSTL | ▲ Buy | Option Exercise | 3,800 | $13K | 3/4/2026 | View on chart |
| CSTL | ▼ Sell | Open Market | 5,300 | $145K | 3/3/2026 | View on chart |
| CSTL | ▼ Sell | Open Market | 1,700 | $47K | 3/3/2026 | View on chart |
| CSTL | ▼ Sell | Tax Withholding | 3,611 | $100K | 3/3/2026 | View on chart |
| CSTL | ▲ Buy | Grant | 8,124 | $0 | 1/12/2026 | View on chart |
| CSTL | ▼ Sell | Open Market | 4,496 | $168K | 12/11/2025 | View on chart |
| CSTL | ▲ Buy | Option Exercise | 6,170 | — | 12/10/2025 | View on chart |
| CSTL | ▼ Sell | Tax Withholding | 2,758 | $105K | 12/10/2025 | View on chart |
| CSTL | ▼ Sell | Tax Withholding | 6,534 | $250K | 12/9/2025 | View on chart |
| CSTL | ▲ Buy | Option Exercise | 14,616 | — | 12/9/2025 | View on chart |
| CSTL | ▼ Sell | Open Market | 5,388 | $189K | 11/11/2025 | View on chart |
| CSTL | ▲ Buy | Option Exercise | 9,744 | $0 | 8/8/2025 | View on chart |
| CSTL | ▼ Sell | Tax Withholding | 4,356 | $84K | 8/8/2025 | View on chart |
| CSTL | ▼ Sell | Tax Withholding | 5,448 | $121K | 3/4/2025 | View on chart |
| CSTL | ▲ Buy | Option Exercise | 12,186 | — | 3/4/2025 | View on chart |
| CSTL | ▼ Sell | Open Market | 8,046 | $215K | 2/20/2025 | View on chart |
| CSTL | ▲ Buy | Option Exercise | 2,000 | — | 12/10/2024 | View on chart |
| CSTL | ▼ Sell | Tax Withholding | 900 | $27K | 12/10/2024 | View on chart |
| CSTL | ▲ Buy | Option Exercise | 6,169 | — | 12/10/2024 | View on chart |
| CSTL | ▼ Sell | Tax Withholding | 2,773 | $82K | 12/10/2024 | View on chart |
| CSTL | ▲ Buy | Option Exercise | 14,617 | — | 12/9/2024 | View on chart |
| CSTL | ▼ Sell | Tax Withholding | 6,571 | $203K | 12/9/2024 | View on chart |
| CSTL | ▼ Sell | Open Market | 6,123 | $183K | 11/15/2024 | View on chart |
| CSTL | ▼ Sell | Open Market | 800 | $24K | 11/15/2024 | View on chart |
| CSTL | ▲ Buy | Grant | 9,745 | $0 | 8/9/2024 | View on chart |
| CSTL | ▼ Sell | Tax Withholding | 2,822 | $76K | 8/9/2024 | View on chart |
| CSTL | ▼ Sell | Open Market | 4,600 | $116K | 8/7/2024 | View on chart |
| CSTL | ▼ Sell | Open Market | 5,400 | $141K | 8/7/2024 | View on chart |
| CSTL | ▲ Buy | Option Exercise | 2,000 | — | 12/10/2023 | View on chart |
| CSTL | ▼ Sell | Tax Withholding | 584 | $12K | 12/10/2023 | View on chart |
| CSTL | ▲ Buy | Option Exercise | 6,170 | — | 12/10/2023 | View on chart |
| CSTL | ▼ Sell | Tax Withholding | 1,802 | $36K | 12/10/2023 | View on chart |
| CSTL | ▲ Buy | Option Exercise | 14,617 | — | 12/9/2023 | View on chart |
| CSTL | ▼ Sell | Tax Withholding | 4,269 | $86K | 12/9/2023 | View on chart |
| CSTL | ▲ Buy | Option Exercise | 4,000 | $14K | 4/4/2023 | View on chart |
| CSTL | ▲ Buy | Option Exercise | 2,000 | — | 12/10/2022 | View on chart |
| CSTL | ▼ Sell | Tax Withholding | 589 | $13K | 12/10/2022 | View on chart |
| CSTL | ▲ Buy | Option Exercise | 6,170 | — | 12/10/2022 | View on chart |
| CSTL | ▼ Sell | Tax Withholding | 1,817 | $41K | 12/10/2022 | View on chart |
| CSTL | ▲ Buy | Option Exercise | 4,000 | $14K | 5/12/2022 | View on chart |
| CSTL | ▲ Buy | Grant | 1,114 | — | 4/26/2022 | View on chart |
| CSTL | ▲ Buy | Option Exercise | 2,000 | — | 12/10/2021 | View on chart |
| CSTL | ▼ Sell | Tax Withholding | 895 | $36K | 12/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Castle Biosciences to Release Q3 2026 Results and New Barrett's Data
Castle Biosciences announced it will release its third‑quarter 2026 financial results on Thursday, November 5, and will host a webcast. The company also plans to present new data from three studies on its TissueCypher Barrett’s Esophagus test at the ACG 2026 annual scientific meeting, showing the test can identify elevated risk of progression beyond pathology findings. These updates give the market fresh information on both the company's earnings and the clinical relevance of its main product.
Castle Biosciences to Release Q3 2026 Results and New Barrett's Data. Castle Biosciences announced it will release its third‑quarter 2026 financial results on Thursday, November 5, and will host a webcast. The company also plans to present new data from three studies on its TissueCypher Barrett’s Esophagus test at the ACG 2026 annual scientific meeting, showing the test can identify elevated risk of progression beyond pathology findings. These updates give the market fresh information on both the company's earnings and the clinical relevance of its main product.